A post-surgical infection, also known as a surgical site infection (SSI), refers to infections after a surgical procedure. Such infections can result in poor wound healing and pain and might require further treatment. A post-surgical infection often occurs within 30 days after a surgical procedure. Studies show that the chances of developing such an infection post-surgery are around 1 to 3%. The growth in the volume of surgical procedures, especially among older adults, coupled with the rising focus on infection control protocols is anticipated to aid in the drug pipeline expansion.
Major companies involved in the post-surgical infection pipeline drugs market include MinaPharm Pharmaceuticals and Aesculap AG, among others.
Leading drugs currently under the pipeline include oral Ciprodiazole® and povidone-iodine topical ointment, among others.
The growing number of surgical procedures and the rising incidence of surgical site infections are expected to positively influence the pipeline landscape of post-surgical infection.
The Post-Surgical Infection Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into post-surgical infection drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for post-surgical infection. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The post-surgical infection pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from post-surgical infection.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to post-surgical infection.
A post-surgical infection can cause fever, tenderness, redness, delayed healing, or swelling, among others. There are three types of post-surgical infections: superficial incisional SSI, deep incisional SSI, and organ or space SSI. These infections are commonly caused by the bacteria Streptococcus, Staphylococcus, and Pseudomonas. Age, diabetes, obesity, and smoking are some of the risk factors for developing a post-surgical infection.
Novel antibiotics and alternative therapies, such as antimicrobial peptides and bacteriophage treatments are increasingly being explored to combat resistant pathogens that cause post-surgical infections. Moreover, the rise in multidrug-resistant cases is shifting the focus towards phage therapy and CRISPR-modified bacteriophages to effectively target these bacterial strains.
This section of the report covers the analysis of post-surgical infection drugs based on several segmentations including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III covers a major share of the total clinical trials for post-surgical infection.
The drug molecule categories covered under the post-surgical infection pipeline analysis include small molecules, peptides, polymers, and biologics. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for post-surgical infection.
The EMR report for the post-surgical infection drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in post-surgical infection clinical trials:
Major drugs currently in the drug pipeline are as follows:
Sponsored by MinaPharm Pharmaceuticals, the objective of the clinical trial is to evaluate the efficacy and safety of oral Ciprodiazole® in comparison to ciprofloxacin tablets and metronidazole tablets in pelvi-abdominal infections and after IV antibiotics in post-operative duration. The study is under Phase IV clinical development and has an estimated 312 participants.
This Phase IV clinical study is aimed at evaluating intranasal povidone iodine (PVI) to prevent Staphylococcus aureus surgical site infections following orthopedic fixation procedures for high-energy lower extremity fractures. The interventional study has enrolled about 2000 subjects and is expected to be completed by February 2026.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Post-Surgical Infection Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for post-surgical infection. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within post-surgical infection pipeline insights.
Global Acute Bacterial Skin and Skin Structure Infections Treatment Market
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share